Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Hodgkin Lymphoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Lymphoma (1022
)
Non-Hodgkin’s Lymphoma (887
)
Lymphoma (1022
)
Non-Hodgkin’s Lymphoma (887
)
›
Associations
(59)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
Bv-AVE-PC
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
Bv-AVE-PC
Sensitive
:
A2
NCCN - 3wk
Bv-AVE-PC
Sensitive: A2 - Guideline
NCCN - 3 weeks
Bv-AVE-PC
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
AEPA-CAPDAC
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
AEPA-CAPDAC
Sensitive
:
A2
NCCN - 3wk
AEPA-CAPDAC
Sensitive: A2 - Guideline
NCCN - 3 weeks
AEPA-CAPDAC
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
CVbP
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
CVbP
Sensitive
:
A2
NCCN - 3wk
CVbP
Sensitive: A2 - Guideline
NCCN - 3 weeks
CVbP
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
CHOP
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
CHOP
Sensitive
:
A2
NCCN - 3wk
CHOP
Sensitive: A2 - Guideline
NCCN - 3 weeks
CHOP
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
OEPA
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
OEPA
Sensitive
:
A2
NCCN - 3wk
OEPA
Sensitive: A2 - Guideline
NCCN - 3 weeks
OEPA
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
ABVE-PC
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
ABVE-PC
Sensitive
:
A2
NCCN - 3wk
ABVE-PC
Sensitive: A2 - Guideline
NCCN - 3 weeks
ABVE-PC
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
TNFRSF8 positive
Hodgkin Lymphoma
TNFRSF8 positive
Hodgkin Lymphoma
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
penpulimab
Sensitive: A1 - Approval
penpulimab
Sensitive
:
A1
penpulimab
Sensitive: A1 - Approval
penpulimab
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
AB122
Sensitive: A1 - Approval
AB122
Sensitive
:
A1
AB122
Sensitive: A1 - Approval
AB122
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
R-CHOP
Sensitive: A2 - Guideline
R-CHOP
Sensitive
:
A2
R-CHOP
Sensitive: A2 - Guideline
R-CHOP
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
R-CVP
Sensitive: A2 - Guideline
R-CVP
Sensitive
:
A2
R-CVP
Sensitive: A2 - Guideline
R-CVP
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
everolimus
Sensitive: A2 - Guideline
everolimus
Sensitive
:
A2
everolimus
Sensitive: A2 - Guideline
everolimus
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
carboplatin + etoposide oral + bendamustine
Sensitive: A2 - Guideline
carboplatin + etoposide oral + bendamustine
Sensitive
:
A2
carboplatin + etoposide oral + bendamustine
Sensitive: A2 - Guideline
carboplatin + etoposide oral + bendamustine
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
bendamustine
Sensitive: A2 - Guideline
bendamustine
Sensitive
:
A2
bendamustine
Sensitive: A2 - Guideline
bendamustine
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
nivolumab + brentuximab vedotin
Sensitive: A2 - Guideline
nivolumab + brentuximab vedotin
Sensitive
:
A2
nivolumab + brentuximab vedotin
Sensitive: A2 - Guideline
nivolumab + brentuximab vedotin
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
GemOx
Sensitive: A2 - Guideline
GemOx
Sensitive
:
A2
GemOx
Sensitive: A2 - Guideline
GemOx
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
ICE
Sensitive: A2 - Guideline
ICE
Sensitive
:
A2
ICE
Sensitive: A2 - Guideline
ICE
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
DHAP
Sensitive: A2 - Guideline
DHAP
Sensitive
:
A2
DHAP
Sensitive: A2 - Guideline
DHAP
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
MINE
Sensitive: A2 - Guideline
MINE
Sensitive
:
A2
MINE
Sensitive: A2 - Guideline
MINE
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
BEACOPP
Sensitive: A2 - Guideline
BEACOPP
Sensitive
:
A2
BEACOPP
Sensitive: A2 - Guideline
BEACOPP
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
IGEV
Sensitive: A2 - Guideline
IGEV
Sensitive
:
A2
IGEV
Sensitive: A2 - Guideline
IGEV
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
GVD
Sensitive: A2 - Guideline
GVD
Sensitive
:
A2
GVD
Sensitive: A2 - Guideline
GVD
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
GDP
Sensitive: A2 - Guideline
GDP
Sensitive
:
A2
GDP
Sensitive: A2 - Guideline
GDP
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
EPIC
Sensitive: A2 - Guideline
EPIC
Sensitive
:
A2
EPIC
Sensitive: A2 - Guideline
EPIC
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
BEAM
Sensitive: A2 - Guideline
BEAM
Sensitive
:
A2
BEAM
Sensitive: A2 - Guideline
BEAM
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
rituximab/hyaluronidase
Sensitive: A2 - Guideline
rituximab / hyaluronidase
Sensitive
:
A2
rituximab/hyaluronidase
Sensitive: A2 - Guideline
rituximab / hyaluronidase
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
vinblastine
Sensitive: A2 - Guideline
vinblastine
Sensitive
:
A2
vinblastine
Sensitive: A2 - Guideline
vinblastine
Sensitive
:
A2
TNFRSF8 positive
Hodgkin Lymphoma
TNFRSF8 positive
Hodgkin Lymphoma
AFM13
Sensitive: C2 – Inclusion Criteria
AFM13
Sensitive
:
C2
AFM13
Sensitive: C2 – Inclusion Criteria
AFM13
Sensitive
:
C2
CHD8 mutation
Hodgkin Lymphoma
CHD8 mutation
Hodgkin Lymphoma
sintilimab
Resistant: C3 – Early Trials
sintilimab
Resistant
:
C3
sintilimab
Resistant: C3 – Early Trials
sintilimab
Resistant
:
C3
CELF2 mutation
Hodgkin Lymphoma
CELF2 mutation
Hodgkin Lymphoma
sintilimab
Resistant: C3 – Early Trials
sintilimab
Resistant
:
C3
sintilimab
Resistant: C3 – Early Trials
sintilimab
Resistant
:
C3
ABCC2 underexpression
Hodgkin Lymphoma
ABCC2 underexpression
Hodgkin Lymphoma
nivolumab + brentuximab vedotin
Sensitive: C3 – Early Trials
nivolumab + brentuximab vedotin
Sensitive
:
C3
nivolumab + brentuximab vedotin
Sensitive: C3 – Early Trials
nivolumab + brentuximab vedotin
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login